Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 21 Aug 2024 Planned initiation date changed from 28 Feb 2024 to 30 Sep 2024.
- 29 May 2024 Trial design discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
- 21 Feb 2024 Planned initiation date changed from 30 Jan 2024 to 28 Feb 2024.